William Blair Comments on Penumbra, Inc.’s Q1 2025 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – Equities researchers at William Blair lifted their Q1 2025 EPS estimates for Penumbra in a research report issued on Thursday, August 1st. William Blair analyst M. Kaczor now forecasts that the company will post earnings of $0.72 per share for the quarter, up from their prior forecast of $0.70. The consensus estimate for Penumbra’s current full-year earnings is $2.74 per share. William Blair also issued estimates for Penumbra’s Q3 2025 earnings at $0.94 EPS.

Penumbra (NYSE:PEN) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The company had revenue of $299.40 million during the quarter, compared to the consensus estimate of $298.24 million. Penumbra had a net margin of 1.26% and a return on equity of 8.39%. Penumbra’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.43 EPS.

PEN has been the topic of several other reports. Royal Bank of Canada decreased their price target on shares of Penumbra from $289.00 to $205.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 31st. Citigroup cut Penumbra from a “buy” rating to a “neutral” rating and raised their price objective for the stock from $165.00 to $178.00 in a report on Wednesday, July 31st. Robert W. Baird dropped their target price on Penumbra from $231.00 to $180.00 and set an “outperform” rating for the company in a research note on Wednesday, July 31st. Morgan Stanley decreased their price target on Penumbra from $235.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Wells Fargo & Company downgraded shares of Penumbra from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $289.00 to $150.00 in a research note on Wednesday, July 31st. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $193.60.

Penumbra Trading Down 3.4 %

Penumbra stock opened at $171.44 on Monday. The stock has a 50-day moving average price of $183.89 and a 200 day moving average price of $213.42. Penumbra has a 52 week low of $148.00 and a 52 week high of $302.00. The stock has a market cap of $6.65 billion, a PE ratio of 72.34, a P/E/G ratio of 1.85 and a beta of 0.55. The company has a current ratio of 6.25, a quick ratio of 3.51 and a debt-to-equity ratio of 0.02.

Hedge Funds Weigh In On Penumbra

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Penumbra by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 3,690,660 shares of the company’s stock worth $823,681,000 after purchasing an additional 32,557 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Penumbra by 7.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 118,828 shares of the company’s stock valued at $29,893,000 after acquiring an additional 8,122 shares during the period. Quadrant Capital Group LLC grew its position in shares of Penumbra by 31.3% during the fourth quarter. Quadrant Capital Group LLC now owns 722 shares of the company’s stock worth $182,000 after acquiring an additional 172 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Penumbra during the fourth quarter worth about $7,503,000. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Penumbra by 19.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 265,155 shares of the company’s stock worth $66,697,000 after acquiring an additional 42,876 shares during the period. Institutional investors own 88.88% of the company’s stock.

Insider Activity at Penumbra

In related news, EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Monday, May 13th. The shares were sold at an average price of $207.41, for a total value of $124,446.00. Following the completion of the sale, the executive vice president now owns 63,488 shares in the company, valued at $13,168,046.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Johanna Roberts sold 600 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $207.41, for a total value of $124,446.00. Following the completion of the sale, the executive vice president now directly owns 63,488 shares of the company’s stock, valued at $13,168,046.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $202.52, for a total value of $3,037,800.00. Following the transaction, the chief executive officer now directly owns 927,582 shares in the company, valued at approximately $187,853,906.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,970 shares of company stock valued at $6,428,404. Insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.